Answers are grounded in this paper and cite their sources.
Demonstrates teucvidin's ability to reduce beat rate in cultured cardiomyocytes, indicating a potential therapeutic effect for cardiac health.
Heart failure remains a major cause of cardiovascular morbidity and mortality despite guideline-recommended pharmacological therapies. Recently, we isolated six bioactive compounds: crassifolin B, crassifolin L, chettaphanin I, cyperenoic acid, teucvidin, and methyl 9-(furan-3-yl)-2,7,13-trimethyl-4-oxo-10-oxatricyclo[5.3.3.01,6]trideca-5,8-diene-2-carboxylate from Gentiana kurroo Royle, a Himalayan medicinal plant. Although the potential beneficial effects of G. kurroo extract on tumour, obesity, and hepatic function have been reported, its impact on cardiac function remains unknown. We tested these compounds (0.1–10 μM, 48 h) on foetal rat-derived cardiomyocytes to assess contractile fraction, contraction velocity, beat rate, and cell viability. No compound altered contractile fraction, contraction velocity, or cell viability. Five compounds did not change beat rate while teucvidin significantly reduced beat rate across multiple concentrations. Although the mechanism of teucvidin’s effect on contractile function was unclear, we found teucvidin potentially suppressed beat rate without impairing contractility or cell viability in cultured cardiomyocytes derived from foetal rats.
No takes yet. Share an insight, caveat, or question.
Sato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: